NUB1 protein localization as a prognostic modifier in ER-negative breast cancer

Breast cancer remains a heterogeneous disease in which prognostic stratification, particularly within estrogen receptor (ER)-negative subtypes, remains clinically challenging. While genomic and transcriptomic profiling have advanced risk classification, protein-level regulation and subcellular localization are rarely incorporated into prognostic frameworks. NEDD8 ultimate buster 1 (NUB1) is a proteostasis-associated protein involved in degradation of ubiquitin-like modifiers and regulation of cell-cycle progression. Emerging evidence suggests that altered subcellular distribution of NUB1, rather than expression alone, associates with aggressive tumor behavior in ER-negative disease. In this editorial, we argue that NUB1 serves as a demonstrator protein illustrating how localization-dependent biology can refine prognostic stratification. Drawing on tissue-based outcome associations and paired primary–metastatic observations, we propose that loss of cytoplasmic NUB1 highlights a biologically distinct poor-outcome subset within ER-negative breast cancer. We further discuss validation priorities and practical considerations for incorporating localization-aware biomarkers into pathology workflows.